1. Transforming the prostatic tumor microenvironment with oncolytic virotherapy
- Author
-
Matthew J. Atherton, Kyle B. Stephenson, Fanny Tzelepis, David Bakhshinyan, Jake K. Nikota, Hwan Hee Son, Anna Jirovec, Charles Lefebvre, Anna Dvorkin-Gheva, Ali A. Ashkar, Yonghong Wan, David F. Stojdl, Eric C. Belanger, Rodney H. Breau, John C. Bell, Fred Saad, Sheila K. Singh, Jean-Simone Diallo, and Brian D. Lichty
- Subjects
mg1-maraba ,prostatic carcinoma ,vaccination ,tumor microenvironment ,steap ,Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Prostate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile oncolytic virus capable of lethally infecting a variety of prostatic tumor cell lines alongside primary PCa biopsies and exerts direct oncolytic effects against large TRAMP-C2 tumors in vivo. An oncolytic immunotherapeutic strategy utilizing a priming vaccine and intravenously administered MG1-Maraba both expressing the human six-transmembrane antigen of the prostate (STEAP) protein generated specific CD8+ T-cell responses against multiple STEAP epitopes and resulted in functional breach of tolerance. Treatment of mice with bulky TRAMP-C2 tumors using oncolytic STEAP immunotherapy induced an overt delay in tumor progression, marked intratumoral lymphocytic infiltration with an active transcriptional profile and up-regulation of MHC class I. The preclinical data generated here offers clear rationale for clinically evaluating this approach for men with advanced PCa.
- Published
- 2018
- Full Text
- View/download PDF